Adalimumab Dosing for Hidradenitis Suppurativa
For adults and adolescents ≥12 years with moderate-to-severe HS, initiate adalimumab with a loading dose of 160 mg at week 0, followed by 80 mg at week 2, then 40 mg weekly starting at week 4. This is the FDA-approved regimen that demonstrated superior efficacy in the pivotal PIONEER trials 1, 2, 3.
Standard Dosing Regimen
The evidence-based dosing algorithm is:
- Week 0: 160 mg subcutaneous (loading dose)
- Week 2: 80 mg subcutaneous
- Week 4 onward: 40 mg weekly (maintenance)
This regimen achieved HiSCR response rates of 42% (PIONEER I) and 59% (PIONEER II) at 12 weeks, significantly superior to placebo (26% and 28%, respectively) 1, 3. The weekly maintenance dosing (40 mg/week) proved more effective than every-other-week dosing in phase 2 trials, with 17.6% achieving clear/minimal/mild disease versus 9.6% with biweekly dosing 1.
Pediatric Considerations (Ages 12-17)
For adolescents ≥12 years, use the same adult dosing regimen 4, 2. The 2025 North American guidelines strongly recommend adalimumab for pediatric patients 12 years and older 4. Pharmacokinetic modeling confirms adolescents achieve similar drug concentrations to adults with this regimen 2. Real-world data from 65 adolescent patients showed 76.9% achieved HiSCR at 6 months with excellent safety 5.
Alternative Maintenance Dosing
An alternative FDA-approved maintenance regimen is 80 mg every 2 weeks after the standard loading doses 2. While both 40 mg weekly and 80 mg biweekly are approved, the evidence favors weekly dosing:
- Weekly dosing maintains steady-state trough concentrations of 7-11 mcg/mL 2
- Biweekly dosing may result in subtherapeutic troughs between doses
- One comparative study found no statistical difference in outcomes between regimens, though both groups improved significantly 6
Dose Intensification for Inadequate Response
For patients with inadequate response to 40 mg weekly, consider intensification to 80 mg weekly 7. Key decision points:
- Approximately 40% of initial non-responders at 12 weeks achieve response by 36 weeks with continued standard dosing 1
- Therapeutic drug monitoring suggests optimal trough levels ≥10.7 mcg/mL correlate with better response 8
- Limited evidence supports 80 mg weekly for severe/refractory cases, with favorable safety profiles 7
- Real-world data shows the adolescent-labeled dose (40 mg every other week) frequently requires intensification 5
Critical Caveats
Do not use 40 mg every other week as maintenance in HS—this dosing failed to meet efficacy endpoints in multiple trials and is inferior to weekly dosing 1. This differs from adalimumab dosing for other indications like rheumatoid arthritis.
Expect delayed response: Nearly half of week-12 responders lost response by week 36, while 40% of non-responders converted to responders with continued treatment 1. This supports maintaining therapy for at least 36 weeks before declaring treatment failure.
Monitor for anti-drug antibodies: Antibodies to adalimumab reduce serum concentrations and are associated with treatment failure 2, 8. Consider therapeutic drug monitoring if response is inadequate, particularly before dose escalation.
Concomitant antibiotics: In PIONEER II, 19% of patients continued tetracycline-class antibiotics during the trial 1. While not required, this combination may be considered for additional benefit.
The most recent 2025 network meta-analysis of phase III trials ranked adalimumab weekly as the most effective biologic for HS, with significant superiority over secukinumab and numerical superiority over bimekizumab, while also demonstrating the best safety profile 9.